Stay updated with breaking news from Patients Under. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While colon cancer rates are declining in people ages 65 and older, they are increasing by 2% a year in people ages 50 to 54, as well as in people younger than
Hyderabad is well-known for its modernity, modern cultural heritage and also its
The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent...
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...